ACT-539313: Difference between revisions
Content deleted Content added
←Created page with '{{Drugbox | Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = 4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(''R'')-3-(3-[1,2,3]triazol-2-yl-benzyl)morpholin-4-yl]methanone | image = | width = <!--Clinical data--> | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Oral | class = Orexin rec...' |
(No difference)
|
Revision as of 02:55, 11 May 2022
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Drug class | Orexin receptor antagonist |
| Pharmacokinetic data | |
| Elimination half-life | 3.3–6.5 hours[1][2] |
| Identifiers | |
| |
ACT-539313 is an orexin antagonist medication which is under development for the treatment of binge eating disorder and was previously under development for the treatment of anxiety disorders.[3][4][5][6][1][2] It is an orally active small-molecule compound with an elimination half-life of 3.3 to 6.5 hours and acts as a selective orexin OX1 receptor antagonist (1-SORA).[3][1][2] As of May 2022, the drug is in phase 2 clinical trials for binge eating disorder.[3] ACT-539313 was originated by Idorsia Pharmaceuticals and is under development by Actelion Pharmaceuticals.[3]
References
- ^ a b c Kaufmann P, Ort M, Golor G, Kornberger R, Dingemanse J (July 2020). "First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist". Br J Clin Pharmacol. 86 (7): 1377–1386. doi:10.1111/bcp.14251. PMC 7319015. PMID 32067262.
- ^ a b c Kaufmann P, Ort M, Golor G, Kornberger R, Dingemanse J (June 2021). "Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313". Prog Neuropsychopharmacol Biol Psychiatry. 108: 110166. doi:10.1016/j.pnpbp.2020.110166. PMID 33159976.
- ^ a b c d https://adisinsight.springer.com/drugs/800049623
- ^ Jacobson LH, Hoyer D, de Lecea L (May 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". J Intern Med. 291 (5): 533–556. doi:10.1111/joim.13406. PMID 35043499.
- ^ Yaeger, Jazmine D.W.; Krupp, Kevin T.; Gale, Jason J.; Summers, Cliff H. (December 2020). "Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity". Medicine in Drug Discovery. 8: 100059. doi:10.1016/j.medidd.2020.100059. ISSN 2590-0986.
- ^ Caldirola D, Alciati A, Cuniberti F, Perna G (2021). "Experimental Drugs for Panic Disorder: An Updated Systematic Review". J Exp Pharmacol. 13: 441–459. doi:10.2147/JEP.S261403. PMC 8055642. PMID 33889031.
{{cite journal}}: CS1 maint: unflagged free DOI (link)
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |